lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-12. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Reactions == Thionyl tetrafluoride reacts with water to make hydrofluoric acid, sulfurofluoridic acid, and sulfuryl difluoride. Mercury can strip off fluoride to make thionyl fluoride and mercurous fluoride. Strong bases result in formation of fluoride and fluorosulfate ions. Reactions with the strong Lewis acids, such as AsF5 and SbF5, result in the formation of trifluorosulfoxonium cation [SOF3]+ and the corresponding salts [SOF3]+[AsF6]− (trifluorosulfoxonium hexafluoroarsenate(V)) and [SOF3]+[SbF6]− (trifluorosulfoxonium hexafluoroantimonate(V)), respectively.
Firefighters hit the demonstrators with powerful water cannons, and the police continued to beat and arrest people. Protesters managed to build a defensible barricade in front of the Dunărea ("Danube") restaurant, which stood until after midnight, but was finally torn apart by government forces. Intense shooting continued until after 03:00, by which time the survivors had fled the streets. Records of the fighting that day include footage shot from helicopters that were sent to raid the area and record evidence for eventual reprisals, as well as by tourists in the high tower of the centrally located InterContinental Hotel, next to the National Theatre and across the street from the university. It is likely that in the early hours of 22 December that the Ceaușescus made their second mistake. Instead of fleeing the city under cover of night, they decided to wait until morning to leave. Ceaușescu must have thought that his desperate attempts to crush the protests had succeeded, because he apparently called another meeting for the next morning. However, before 07:00, his wife Elena received the news that large columns of workers from many industrial platforms (large communist-era factories or groups of factories concentrated into industrial zones) were heading towards the city centre of Bucharest to join the protests. The police barricades that were meant to block access to Piața Universității (University Square) and Palace Square proved useless. By 09:30 University Square was jammed with protesters.
Dextrose monohydrate is the hydrated form of D-glucose, meaning that it is a glucose molecule with an additional water molecule attached. Its chemical formula is C6H12O6 · H2O. Dextrose monohydrate is also called hydrated D-glucose, and commonly manufactured from plant starches. Dextrose monohydrate is used as the predominant type of dextrose in food applications, such as beverage mixes—it is a common form of glucose widely used as a nutrition supplement in production of foodstuffs. Dextrose monohydrate is primarily consumed in North America as a corn syrup or high-fructose corn syrup. Anhydrous dextrose, on the other hand, is glucose that does not have any water molecules attached to it. Anhydrous chemical substances are commonly produced by eliminating water from a hydrated substance through methods such as heating or drying up (desiccation). Dextrose monohydrate can be dehydrated to anhydrous dextrose in industrial setting. Dextrose monohydrate is composed of approximately 9.5% water by mass; through the process of dehydration, this water content is eliminated to yield anhydrous (dry) dextrose. Anhydrous dextrose has the chemical formula C6H12O6, without any water molecule attached which is the same as glucose. Anhydrous dextrose on open air tends to absorb moisture and transform to the monohydrate, and it is more expensive to produce. Anhydrous dextrose (anhydrous D-glucose) has increased stability and increased shelf life, has medical applications, such as in oral glucose tolerance test.
==== Local application to the breasts ==== Transdermal application of progesterone with the intention of systemic therapy should not be equated with local treatment. The site of application of transdermal progesterone has been found to significantly influence its absorption. When transdermal progesterone is applied to the breasts, high concentrations within breast tissue have been observed. In one study, a 3- to 5-fold increase in local progesterone levels in the breast was observed with 50 mg transdermal progesterone in an alcohol/water-based gel applied to each breast in premenopausal women. In another study, a 70- to 110-fold increase in local concentrations of progesterone in the breasts was measured with application of a hydroalcoholic gel to the breasts in premenopausal women. A study observed a significant increase in circulating levels of progesterone when it was applied as a topical ointment to the breasts but not when it was applied to other areas like the thigh or abdomen. However, two other studies observed no apparent increase in circulating levels of progesterone with transdermal application of progesterone to the breasts. On the basis of its 10% transdermal bioavailability when applied to the breasts, a 50 mg dose of progesterone applied transdermally may result in a local concentration of progesterone in the breasts equivalent to 5 mg.
Sources: en.wikipedia.org
== Skeptical view of therapeutic touch == In examinations of the existing literature on therapeutic touch, it has been observed that these studies tend only to cite research that favours the desired findings. There have been studies focused on therapeutic touch that have failed to include any research that has contradictory findings, despite their obligation to report it. Some studies, have also lacked appropriate controls, and so have appeared at first glance to show the effectiveness of therapeutic touch, yet have returned nonsignificant results when replicated; this is the case with the Grad, Cadoret, and Paul study. Researcher bias has been found in studies examining therapeutic touch. A study on therapeutic touch by Wirth, in which more than half of the subjects being treated by this therapy had healed by day 16, with no healing shown in the control group, appeared successful. However, closer examination reveals that there were several trials conducted, that only two of the five trials were successful, and that the control group healed as well or better than the treatment group in the other three trials. Similarly, Turner declared that a successful result of his work would provide "the first real scientific evidence there is for therapeutic touch," suggesting bias. Much such research has also failed to be replicated.
==== Chlorine tablets ==== Sodium dichloroisocyanurate or troclosene sodium, more commonly shortened as NaDCC, is a form of chlorine used for disinfection. It is used by major non-governmental organizations such as UNICEF to treat water in emergencies. Sodium dichloroisocyanurate tablets are available in a range of concentrations to treat differing volumes of water to give the World Health Organization's recommended 5ppm available chlorine. They are effervescent tablets allowing the tablet to dissolve in a matter of minutes.
Referring to the character of the eruption and the rapidity of its development, modified smallpox occurred mostly in previously vaccinated people. It was rare in unvaccinated people, with one case study showing 1–2% of modified cases compared to around 25% in vaccinated people. In this form, the prodromal illness still occurred but may have been less severe than in the ordinary type. There was usually no fever during the evolution of the rash. The skin lesions tended to be fewer and evolved more quickly, were more superficial, and may not have shown the uniform characteristic of more typical smallpox. Modified smallpox was rarely, if ever, fatal. This form of variola major was more easily confused with chickenpox.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.